As of Mar 28, 2026, Innova Captab Ltd (Pharma - API) has a deep value score of 43/100 (rated Average). Earnings are accelerating. 1Y return vs Nifty 500: -22%.
Deep value thesis based on recent earnings • Updated Mar 21, 2026
Innova Captab is transitioning from a struggling pharma player to a high-growth CDMO and Branded Generics business with revenue surging 42.3% YoY in Q3 FY26, driven by facility ramp-ups and regulatory approvals that are finally translating to margin stability.
Verdict
TURNAROUND_IN_PROGRESS
Re-rating catalysts over the next 2-4 quarters • Updated Mar 21, 2026
Management guidance indicates Jammu facility will contribute positively to profits next year, adding ₹15-20 Cr quarterly PAT.
Impact: +₹15 Cr revenue
“Jammu facility revenue jumped to ₹89 Cr in Q3 (from ₹60 Cr last quarter) with UK-MHRA and PIC/s certifications enabling export growth.”
New US/EU contracts from recent certifications expected to extend order book from current 12 months.
Impact: +₹25 Cr revenue
“CDMO business generated ₹298.7 Cr in Q3 FY26, up 29% YoY from ₹231.6 Cr with exports forming 35% of Q3 revenue mix.”
Potential first meaningful payout since FY23, signaling confidence in cash flow sustainability.
“Board met on Jan 23, 2026 to review Q3 results and consider interim dividend.”
Risks that could prevent re-rating or deepen the value trap
If receivables days exceed 110
Impact: -300 bps margin impact
Management view: Management acknowledged working capital challenges but expects improvement with Jammu facility profitability.
Monitor: Receivables days
If pledge increases further
Management view: No official comment on reducing pledge levels.
Monitor: Promoter pledge percentage
If API prices fall 15%+ in key markets
Impact: -400 bps margin impact
Management view: Management is hedging exposure through long-term contracts with key customers.
Monitor: API price index
Forward-looking targets from management for FY27
Revenue Growth Target
25%
Implied PAT Growth
30%
OPM Guidance
16.5%
Capex Plan
₹50 Cr
Credit Growth Target
20%
NIM Guidance
0%
Key Milestones
• Jammu facility EBITDA positive by Q1 FY27
• CDMO order book to 18 months by Q3 FY27
• Interim dividend in Q4 FY26
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +42% | +16% | Stable |
| PAT (Net Profit) | +24% | +26% | Stable |
| OPM | 15.0% | 0 bps | Stable |
The above analysis is AI-generated from publicly available financial data. This is educational research only — not investment advice. Last updated Mar 21, 2026.
Based on publicly available financial data. This is educational research, not investment advice.
Innova Captab Ltd has a deep value score of 43/100 (rated Average). This score is calculated from three components
Innova Captab Ltd's quarterly profit (PAT) growth trajectory
Innova Captab Ltd is underperforming the market despite improving earnings — this is the core deep value thesis
Innova Captab Ltd's earnings momentum is Steady — consistent growth.
Innova Captab Ltd's valuation metrics
Innova Captab Ltd's revenue and margin trends
Innova Captab Ltd's trailing twelve month (TTM) performance
Innova Captab Ltd key facts
Innova Captab Ltd shows limited deep value signals currently — score is 43/100 (Average). Monitor for improvement.
Other deep value stocks in Pharma - API
Pharma - API deep value sector overview
Deep value investing studies stocks that are underperforming the market despite showing improving fundamentals. The thesis is that the market has not yet recognized the earnings recovery, creating a potential valuation gap. It requires patience — recovery can take several quarters.
The deep value score (0-100) combines three factors:
- Earnings (0-40 pts): PAT growth across last 3 quarters, acceleration, and consecutive growth - Underperformance (0-35 pts): How much the stock trails Nifty 500 over 1Y, 6M, 3M (deeper underperformance = higher score) - Quality (0-25 pts): Revenue growth, margin trends, and valuation metrics (PEG, P/B)
Higher score indicates a stronger contrarian research signal.
Innova Captab Ltd has 3 key growth catalysts identified from recent earnings analysis
Innova Captab Ltd has 3 key risks worth monitoring
The above FAQs are generated from publicly available earnings data. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.
